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The funding policies of the NIH have made it increasingly difficult for young researchers to 
procure research funds. This threatens to drive a whole generation of young people away 
from careers in basic biomedical research.Cell 126, July 14, 2006 ©2006 Elsevier Inc. The numbers are striking. Over the 
past generation, the age at which 
American biomedical researchers 
with PhD degrees succeed in obtain-
ing their first R01 award from the 
National Institutes of Health (NIH) 
has increased from 34.2 to 41.7 
years of age. As a consequence, 
the biomedical community in the 
United States lives with the pros-
pect of relying on an aging cohort 
of researchers to direct its research 
projects. The reasons for this are 
surely complex, but the long-term 
trend is ominous for the future of 
the American research enterprise. 
Why are R01 grants becoming so 
difficult to obtain? And what does 
this portend for future innovation 
and discovery by NIH-supported 
researchers?
The history of the last half-cen-
tury demonstrates in a compelling 
fashion that much of the innovation 
in American biomedical research 
comes from young researchers work-
ing in relatively small, highly mobile, 
creative research groups. These 
groups operate opportunistically to 
exploit new research findings and to 
catapult our understanding forward, 
often doing so with stunning rapidity. 
These younger researchers, ranging 
from predoctoral students to prin-
cipal investigators in their 30s and 
early 40s, have time and again deliv-
ered on the promise that unfettered 
imaginations and boundless energy 
are uniquely suited to generate new 
conceptual paradigms in biology. 
These young people represent the 
cadre of researchers whose vitality 
we must preserve at all costs. These 
people are the last who should suffer 
from a flat NIH budget.Those who lead the U.S. Fed-
eral research agencies in Bethesda, 
Maryland, have lost sight of this sim-
ple truth. As a consequence, Ameri-
can biomedical research is increas-
ingly reverting to models of research 
organization that have held back 
scientific progress in many other 
parts of the world. In these models, 
researchers acquire their scientific 
independence only when in their 40s 
and even 50s, long after the peak of 
their scientific creativity has passed.
The failure to recognize and halt 
this trend is compounded by another 
problem. As time goes on, ever-
larger proportions of NIH funds are 
diverted to funding research col-
laboratives of various sizes to the 
detriment of small, investigator-ini-
tiated projects. Perhaps those in 
power have been influenced by the 
obvious successes of the Human 
Genome Sequencing Project and 
the bounty of useful information that 
it has yielded. Those who control 
the scientific purse strings seem to 
have lost sight of the fact that this 
undoubted success does not provide 
a useful template for how most dis-
covery research is conducted. In the 
case of the National Cancer Institute, 
this vision of grand projects and their 
utility has caused this particular Insti-
tute to invest large amounts of funds 
in proteomics, nanotechnology, and 
a massive software development 
program that aspires to make the 
data systems of American research 
hospitals intercompatible. Implied 
in the launching of these large-scale 
projects is the notion that if small-
scale projects yield relatively small 
advances, much larger projects will 
yield proportionately more.Stated differently, some live with 
the notion that the era of small-scale 
discovery research has passed and 
that the time has finally arrived to 
organize large research consortia 
to move things forward more effec-
tively. The truth is otherwise: the 
vast majority of recent leaps forward 
have come, as they did in the past, 
from relatively small research groups 
that have been given the license to 
venture out and explore the outer 
boundaries of existing understand-
ing. Large-scale projects surely have 
their place, and technology advances 
made over the past decade dictate 
that some of these must be sup-
ported in order for science to be 
moved forward. But in the end, the 
viability of small research groups and 
investigator-initiated research should 
be paramount and must be pro-
tected; indeed, it must be the num-
ber one priority for those who invest 
in biomedical research. Large col-
laborative research programs tend to 
stifle discovery research rather than 
expediting it.
Woven into the thinking of some 
in positions of power and influence 
is yet another issue, which is equally 
pernicious: that the research process 
involves too much competition, and 
that scientific output would increase 
immeasurably if only researchers were 
induced (or even forced) to collaborate 
with one another more frequently. The 
reality is that successful laboratory 
researchers are highly opportunistic, 
continually forging new collaborations 
when they are deemed advantageous 
and dissolving these collaborations as 
soon as they have outlived their util-
ity. Ignoring this dynamic, the NIH has 
 contrived numerous funding devices 
for encouraging scientific collabora-
tions, by bringing multiple research 
groups under a common funding 
umbrella; often, these research col-
laboratives are funded for periods that 
extend far beyond the time when their 
utility has ceased.
As a consequence of these trends, 
small-scale discovery research is 
under siege, yet it is precisely such 
small-scale science that attracts the 
best and the brightest of our young 
people. Many of those who are train-
ing for careers in research do not 
look forward to working as members 
of large research consortia, in which 
they will only serve as small cogs in 
very large wheels.10 Cell 126, July 14, 2006 ©2006 ElsevieCompounding this is the current 
deplorable state of funding investi-
gator-initiated research: pay lines in 
which only 10% of submitted grant 
applications are funded constitute 
profound disincentives for research-
ers. Why should a young person 
invest in the laborious task of writing 
an NIH grant application that has only 
a minimal chance of being funded?
These factors, when taken 
together, have made careers in bio-
medical research increasingly unat-
tractive for many young people. 
Imagine the prospects of predoc-
toral students starting out in their 
early 20s, who confront a wait of two 
decades until they can procure their r Inc.first R01 grant, become scientifically 
independent, and flex their scientific 
muscles for the first time.
Increasingly, these factors dictate 
that the best and the brightest are 
not entering our ranks. As a conse-
quence, those of us who conduct 
discovery research are confronting 
the prospect of a lost generation, 
a wide gap in our ranks, as bright 
young people look elsewhere to dis-
cover their career paths. The marvel-
ous engine of American biomedical 
research that was constructed dur-
ing the last half of the 20th century is 
being taken apart, piece by piece. 
We will all pay for this destruction for 
decades to come.
